TABLE 3.
Protective efficacy of recombinant flagellum-secreted proteins against C. jejuni 81-176 or C. jejuni CG8486 challenge
| Vaccination protein | Presence of LTR192Gb | Challenge withc:
|
|||
|---|---|---|---|---|---|
| 81-176
|
CG8486
|
||||
| Illness index (mean ± SD) | Efficacy (%) | Illness index (mean ± SD) | Efficacy (%) | ||
| PBSa | −/+ | 1.16 ± 0.21 | NA | 1.25 ± 0.24 | NA |
| FspA1 | − | 0.49 ± 0.17† | 57.8 | 0.69 ± 0.21† | 44.8 |
| FspA1 | + | 0.42 ± 0.14† | 63.8 | 0.86 ± 0.28† | 31.2 |
| FspA2 | − | 0.95 ± 0.12 | 18.1 | 0.77 ± 0.27† | 38.4 |
| FspA2 | + | 1.20 ± 0.29 | −3.4 | 0.66 ± 0.18† | 47.2 |
| FlaC | − | 1.03 ± 0.27 | 11.2 | ND | NA |
| FlaC | + | 0.95 ± 0.29 | 18.1 | ND | NA |
a
There was no difference in challenge outcome among animals receiving PBS alone or PBS with 1 μg of LTR192G; therefore data were pooled for efficacy calculations.
b
−, absent; +, present.
c
†, Significant difference (P < 0.05) with PBS group; NA, not applicable; ND, not determined.